Separate teams led by researchers from New York University and Columbia University have identified mutations in 5ʹ-nucleotidase
cytosolic II that predict
relapse, drug resistance and poor prognosis in acute lymphoblastic leukemia.1,2
Inhibiting the enzyme could improve disease outcomes and sensitize some
relapsed patients to marketed acute lymphoblastic leukemia therapies.
Both teams told SciBX that their
next steps included designing NT5C2 inhibitors. The molecules likely would be
used to resensitize resistant ALL to standard therapies like 6-MP and 6-TG.
Martz, L. SciBX 6(9); doi:10.1038/scibx.2013.208 Published online March
1. Meyer, J.A. et al.
Nat. Genet.; published online Feb. 3, 2013; doi:10.1038/ng.2558 Contact:
William L. Carroll, NYU Cancer Institute, New York, N.Y. e-mail: email@example.com
2. Tzoneva, G. et al. Nat.
Med.; published online Feb. 3, 2013; doi:10.1038/nm.3078 Contact:
Adolfo Ferrando, Columbia University, New York, N.Y. e-mail: firstname.lastname@example.org
C.-H. & Evans, W.E. et al. N. Engl. J. Med. 354, 166-178
AND INSTITUTIONS MENTIONED
Albert Einstein College of Medicine of Yeshiva University, New York, N.Y.
Cancer Institute Padua, Padua, Italy
Cancer Research UK, London, U.K.
Charité-University Hospital Berlin, Berlin, Germany
Children's Hospital Colorado, Aurora, Colo.
Columbia University, New York, N.Y.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Newcastle University, Newcastle upon Tyne, U.K.
New York University, New York, N.Y.
Shaare Zedek Medical Center, Jerusalem, Israel
St. Jude Children's Research Hospital, Memphis, Tenn.
Technion-Israel Institute of Technology, Haifa, Israel
University of Colorado Denver School of Medicine, Aurora, Colo.
University of Padua, Padua, Italy
Weill Cornell Medical College, New York, N.Y.